The QualityStocks Daily Tuesday, February 21st, 2023

Today's Top 3 Investment Newsletters

The Stock Dork(ARBE) $6.4000 +47.13%

MarketClub Analysis(MOB) $2.1900 +41.29%

360wallstreet(TRKA) $0.2820 +28.12%

The QualityStocks Daily Stock List

Lichen China (LICN)

Money Wealth Matters reported earlier on Lichen China (LICN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lichen China Limited (NASDAQ: LICN) is an investment holding firm that is engaged in the provision of financial and taxation, education support, and software and maintenance services in China.

The firm has its headquarters in Jinjiang, the People’s Republic of China and was incorporated in 2016, on April 13th by Li Ya. It operates as part of the specialty business services industry, under the industrials sector. The firm serves consumers in China.

The company operates as a subsidiary of Silver Sky Investment Limited. With almost two decades of operation history, it has gained substantial experience and established a solid reputation with a proven track record in the PRC.

The enterprise provides financial and taxation-related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation services; and education support services, including marketing, operational, and technical support, as well as sale of teaching and learning materials. It also offers Lichen Education Accounting Practice System V1.0, a financial and taxation training software, and academic affairs management system to partnered institutions under partnership agreements, as well as offers software installation, training, and after sales technical and maintenance support services.

The firm remains focused on expanding its financial and taxation solution services, strengthening research and development and improving brand recognition through multi-channel marketing. This will bring in additional revenues and investments into the firm and help create value for its shareholders while also bolstering the firm’s overall growth.

Lichen China (LICN), closed Tuesday's trading session at $2.17, off by 14.902%, on 464,775 volume. The average volume for the last 3 months is 292,189 and the stock's 52-week low/high is $2.01/$5.82.

Emeren Group (SOL)

The Street, StocksEarning, MarketBeat, Zacks, Money Morning, SmarTrend Newsletters, FreeRealTime, China Vesting, Streetwise Reports, Trade of the Week, StreetInsider, QualityStocks,, Alternative Energy, Investor Ideas, Taipan Daily, Top Stock Picks, InvestorPlace, Daily Markets, TradersPro, Trading Concepts, Energy and Capital, StreetAuthority Daily, ProfitableTrading, MarketClub Analysis, Inside Investing Daily, Hit and Run Candle Sticks, AllPennyStocks, Cabot Wealth, PoliticsAndMyPortfolio, InvestorIntel, StockEarnings, Schaeffer's, PennyOmega, TopStockAnalysts, Daily Trade Alert, The Online Investor, CRWEWallStreet, CRWEPicks, DrStockPick, TopPennyStockMovers, Street Insider, BUYINS.NET, BestOtc, AnotherWinningTrade, Trades Of The Day, CRWEFinance, PennyToBuck, FeedBlitz, Green Chip Review, Green Chip Stocks, StockMarketWatch, Stockhouse, StockHotTips, Stock Research Newsletter, Jason Bond, Market FN, Stock Analyzer, smartOTC, and The Best Newsletters reported earlier on Emeren Group (SOL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Emeren Group Ltd (NYSE: SOL) (FRA: VQKB) (BMV: SOLN) is a pure solar project developer and operator focused on the development, building, operation and sale of solar power projects in Asia, North America and Europe.

The firm has its headquarters in Stamford, Connecticut and was incorporated in 2005. Prior to its name change in January 2023, the firm was known as ReneSola Ltd. It operates as part of the solar industry, under the technology sector. The firm serves consumers around the globe.

The company’s strategy is to pursue project development opportunities, primarily in the United States and Europe. It operates through the Electricity Generation revenue, EPC Services (Engineering, Procurement and Construction) and Solar Power Project Development segments. It generates most of its revenue from the project development segment. The company operates in Hungary, Poland, France, Turkey, England, Romania, Canada, United States and China.

The enterprise is involved in the generation and sale of electricity as well as the development of community solar gardens. It also sells project rights while its EPC business offers balance-of-system components, procurement of solar modules and construction contracting and management services as well as engineering design. As of December 2021, the enterprise operated roughly 100 solar power projects with an estimated capacity of 180 megawatts.

The company, which recently announced its latest financial results, remains focused on achieving the UN Sustainable Development Goals and contributing to cleaner energy alternatives and an overall greener future. This will help to better meet client needs while also generating additional revenues for the company.

Emeren Group (SOL), closed Tuesday's trading session at $4.52, off by 4.034%, on 301,359 volume. The average volume for the last 3 months is 147,761 and the stock's 52-week low/high is $3.46/$8.43.

CalAmp (CAMP)

TopStockAnalysts, StreetAuthority Daily, Dividend Opportunities, ProfitableTrading, StreetInsider, MarketBeat, The Street, Schaeffer's, Barchart,, Zacks, Market Intelligence Center Alert, Daily Dividends, OTC Journal, Trades Of The Day, Trading Concepts, Daily Trade Alert, VectorVest, QualityStocks, Kiplinger Today, Market Report, Stockhouse, The Best Newsletters, Greenbackers, CRWEWallStreet, DrStockPick, PennyOmega, BUYINS.NET, CRWEPicks, OTCJournal, BestOtc, CRWEFinance, Trade of the Week, PennyToBuck, StockHotTips, Profit Confidential, HotOTC, FreeRealTime, StockMarketWatch, StockRich, Stocks That Move, Daily Profit, Street Insider, Penny Detectives, The Motley Fool, InsiderTrades, CrashTrade, CoolPennyStocks, TradingAuthority Daily, BullRally, Wealth Insider Alert, Wyatt Investment Research, StreetAuthority, MadPennyStocks, PennyInvest, PennyTrader Publisher, AllPennyStocks, Money and Markets, MarketClub Analysis, RedChip, SmallCapNetwork, StockEgg, Market Intelligence Center, Insider Wealth Alert, Stealth Stocks, iStockAnalyst, InvestorPlace, Investor Update, Investment House, Investment Contrarians, PennyStockVille and SmallMovesBigGains reported earlier on CalAmp (CAMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CalAmp Corp (NASDAQ: CAMP) (FRA: CF3) is a connected intelligence firm that is engaged in the provision of a data-driven solutions ecosystem to organizations and individuals globally.

The firm has its headquarters in Irvine, California. It operates as part of the communication equipment industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in Europe, the United States, Africa, the Middle East, the Asia-Pacific and Latin America.

The company operates through the Software & Subscription Services and Telematics Products segments. It offers CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate the integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. It also provides telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition to this, the enterprise provides professional services, including project management, engineering services, and installation services. The enterprise sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, auto dealers, original equipment manufacturers, and leasing companies.

The enterprise, whose latest financial results show increases in its revenues, remains focused on accelerating its business model conversion and driving higher profitability. This will bolster the firm’s overall growth.

CalAmp (CAMP), closed Tuesday's trading session at $4.48, off by 3.6559%, on 147,761 volume. The average volume for the last 3 months is 3.434M and the stock's 52-week low/high is $2.96/$7.62.

Azul S.A. (AZUL)

MarketBeat, MarketClub Analysis, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Schaeffer's, Zacks, The Street, StreetInsider, InvestorPlace, TradersPro and BUYINS.NET reported earlier on Azul S.A. (AZUL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Azul S.A. (NYSE: AZUL) (FRA: 8AZA) (BMVF: AZUL4) is a holding firm engaged in the provision of passenger and cargo transportation services.

The firm has its headquarters in Barueri, Brazil and was incorporated in 2008, on January 3rd by David Neeleman. It operates as part of the airlines industry, under the industrials sector. The firm serves consumers around the globe.

The company’s vision is to build the best airline globally. It generates revenues through its aircrafts, primarily from Brazil. Other revenues are usually derived from cargo operations, luggage fares, interest on installment sales, excess luggage, penalties for cancellation of tickets and all items are directly attributed to air transport services. The company operates through its subsidiaries, which include Azul Linhas Aereas Brasileiras SA, which operates all flight activities and TudoAzul SA, which manages the loyalty program.

The enterprise operates daily flights departing from Fort Lauderdale and Orlando. It also schedules flights to more than 100 destinations throughout Brazil. Its service features include passenger seat selection, leather seats, individual entertainment screens with free live television at every seat in all E-Jets, extensive legroom with a pitch of 30 inches or more, complimentary beverage and snack services and free bus service to key airports. It also offers a scheduled cargo transport service with airport-to-airport and door-to-door delivery dubbed Azul Cargo Express.

The firm recently announced a partnership with Flyr Labs, which will optimize its revenue management strategy and help meet increasing customer demands. This will in turn bolster the companies’ overall growth while also creating value for their shareholders.

Azul S.A. (AZUL), closed Tuesday's trading session at $4.3, off by 4.8673%, on 3,474,241 volume. The average volume for the last 3 months is 21,448 and the stock's 52-week low/high is $4.17/$17.39.

Ultralife (ULBI)

Wall Street Resources, SmarTrend Newsletters, ChartPoppers, Pumps and Dumps, StreetAuthority Daily, Dynamic Wealth Report, Stock Spike, SmallCapVoice, QualityStocks, MarketBeat, CoolPennyStocks, HotOTC, M2 Communications, MadPennyStocks,, BullRally, Money Morning, StockEgg, StockOodles, Tiny Gems, Wall Street Greek and MarketClub Analysis reported earlier on Ultralife (ULBI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ultralife Corp. (NASDAQ: ULBI) (FRA: ULB) is a company that is focused on designing, manufacturing, installing and maintaining power, and communication and electronics systems.

The firm has its headquarters in Newark, New York and was incorporated in December 1990 by Arthur M. Liberman. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers globally.

The enterprise operates through the Battery and Energy Products and Communications Systems segments. The Battery and Energy Products segment provides lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables. The Communications Systems segment offers communications systems and accessories to support military communications systems, such as radio frequency amplifiers, power supplies and cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, and integrated communication systems for fixed or vehicle applications comprising vehicle adapters, vehicle installed power enhanced rifleman appliqué systems, and SATCOM systems. This segment's military communications systems and accessories are designed to enhance and extend the operation of communications equipment, such as vehicle-mounted, manpack, and handheld transceivers. In addition, the enterprise sells its 9-volt battery to the broader consumer market through national and regional retail chains and online retailers. It serves government, defense, and commercial sectors.

The company, which recently appointed a new CEO, remains committed to executing its global diversification strategy and acquisitions that’ll position it in new markets. This will generate additional revenues and generate value for its shareholders.

Ultralife (ULBI), closed Tuesday's trading session at $4.06, up 0.246914%, on 21,448 volume. The average volume for the last 3 months is 174,915 and the stock's 52-week low/high is $3.67/$5.78.

Infinity Stone Ventures Corp. (GEMSF)

We reported earlier on Infinity Stone Ventures Corp. (GEMSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Infinity Stone (CSE: GEMS) (OTC: GEMSF) (FSE: B2I) today announce that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The planned dual listing is designed to provide the company with the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in CSE- and OTCQB-listed Infinity Stone. “Building shareholder value and increasing our liquidity is always a high priority for us as a company,” said Zayn Kalyan, CEO of Infinity Stone. “We believe a dual listing on Upstream will act as an excellent vehicle to reach an untapped international market of potential new shareholders.”

To view the full press release, visit

About Infinity Stone Ventures Corp.

Infinity Stone’s mission is to be a diversified, single source supplier for the critical energy metals being used in the clean energy revolution alongside its established SaaS solution portfolio. Infinity Stone is meeting the demand from battery and wind turbine manufacturers, nuclear and hydrogen energy producers, and energy metals speculators by acquiring 100% interest in critical mineral deposits and occurrences in stable mining-friendly jurisdictions, close to final use destinations in North American manufacturing hubs. To register for investor updates, visit

Infinity Stone Ventures Corp. (GEMSF), closed Tuesday's trading session at $0.1223, off by 4.565%, on 183,595 volume. The average volume for the last 3 months is 1.093M and the stock's 52-week low/high is $0.0085/$0.6873.

Hempacco Co. Inc. (HPCO)

QualityStocks, RedChip, The Stock Dork, Money Wealth Matters, MarketClub Analysis and INO Market Report reported earlier on Hempacco Co. Inc. (HPCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hempacco (NASDAQ: HPCO), a vertically integrated hemp manufacturing company, has closed on its upsized underwritten public offering. The offering consisted of an estimated 4,830,000 shares of common stock, including an additional 630,000 shares issued pursuant to the full exercise of the overallotment option by the underwriters. According to the announcement, the common shares were sold for $1.50 per share, resulting in gross proceeds of some $7.245 million before subtracting standard underwriting discounts, commissions and other offering expenses. The company anticipates using the offering’s net proceeds for sales and marketing along with potential acquisitions and upgrades to the company’s existing manufacturing facility, working capital, and other general corporate purposes.

To view the full press release, visit

About Hempacco Co.

Hempacco’s goal is Disrupting Tobacco's(TM) nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff(TM) functional hemp cigarette and rolling paper brand. Hempacco's operating segments include manufacturing of smokables, hemp rolling paper, and cannabinoid sticks; smokable technology development; The Real Stuff brand of functional smokables and rolling paper; Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross; and Snoop Dogg joint venture of hemp-derived products. For more information about the company, please visit

Hempacco Co. Inc. (HPCO), closed Tuesday's trading session at $1.16, off by 4.1322%, on 1,092,820 volume. The average volume for the last 3 months is 407 and the stock's 52-week low/high is $0.74/$41.80.

First Northern Community Bancorp (FNRN) and MarketBeat reported earlier on First Northern Community Bancorp (FNRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

First Northern Community Bancorp (OTCQB: FNRN), holding company for First Northern Bank (“First Northern” or the “Bank”), today reported 2022 annual net income of $15.9 million, or $1.09 per diluted share. This reflected increases of 12% and 14.7%, respectively, when compared to net income of $14.2 million, or $.95 per diluted share, for 2021. In addition, net income for the quarter ended Dec. 31, 2022, totaled $4.7 million, or $.33 per diluted share, compared to net income of $3.2 million, or $.22 per diluted share, for the quarter ended Dec. 31, 2021. “We attribute our record-year performance to robust loan growth and an increasing interest rate environment driving a continuing rise in interest income over the course of the year,” said First Northern’s CEO and President Jeremiah Smith. “We reported record net interest income of $54.7 million for the year when compared to $46.3 million for the year prior, an improvement of $8.5 million or 18.2%. Net interest margin was 3.06% for the year ended 2022, which was a 16.8% or 44 basis-point improvement from the 2.62% reported a year prior. This improvement drove our record net income of $15.9 million for the year ending December 31, 2022, up 12% over the $14.2 million earned one year ago.”

To view the full press release, visit

About First Northern Community Bancorp.

First Northern is an independent community bank that specializes in relationship banking. The Bank, headquartered in Solano County since 1910, serves Solano, Yolo, Sacramento, Placer, and Contra Costa Counties, as well as the west slope of El Dorado County. Experts are available in small-business, commercial, real estate and agribusiness lending, as well as mortgage loans. The Bank is an SBA Preferred Lender. Non-FDIC insured investment and brokerage services are available at every branch location, including Dixon, Davis, West Sacramento, Fairfield, Vacaville, Winters, Woodland, Sacramento, Roseville, Auburn, Rancho Cordova, Colusa, Willows, and Orland. The Bank also has a commercial lending office in Walnut Creek. Real estate mortgage and small-business loan officers are available by appointment in any of the Bank’s 14 branches. First Northern is rated as a Veribanc “Blue Ribbon” and “5-Star Superior” bank by Bauer Financial for the earnings period ended Sept. 30, 2022 ( and ( The Bank can be found on the web at

First Northern Community Bancorp (FNRN), closed Tuesday's trading session at $8.9, up 0.28169%, on 407 volume. The average volume for the last 3 months is 1.459M and the stock's 52-week low/high is $7.25/$10.75.

Bit Digital Inc. (BTBT)

QualityStocks, MarketClub Analysis, StocksEarning, Schaeffer's, TradersPro, InvestorPlace, StockEarnings, MarketBeat and Daily Trade Alert reported earlier on Bit Digital Inc. (BTBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

It was a catastrophic event for the crypto fraternity when FTX folded in November. This was termed the Lehman moment, when a giant within the industry buckled, the damage spread, and reluctant regulators suddenly had an epiphany and went on a public rampage to improve their image. The crypto industry is now plunging into the twilight zone: the Dodd Frank era. (Frank is the 2010 legislation Congress passed supposedly fixing the lax oversight within the banking industry that sunk the financial world into the worst historical financial abyss ever.)

As the market burst into a mega-dollar enterprise, proponents grappled with an ill-equipped regulatory infrastructure unable to handle the crypto industry. When FTX filed for bankruptcy, federal and state officials escalated their efforts to tame the crypto industry, a move that has irked major crypto companies badly. Last week, the Senate committee on Banking held a joint meeting titled “Crypto Crash: Why there is a need for financial safeguarding of digital assets.”

Senator Sherrod Brown in his introductory remarks on the floor of the meeting reportedly said that it was fortunate that the contagion resulting from FTX’s collapse didn’t shake up the wider financial system, but such a risk was possible as the industry becomes more interwoven into the broader financial fabric of the nation. The crypto crisis exposed unsuspecting investors to possible loss because the digital assets such as cryptocurrencies, stablecoins and investment tokens are pseudo products run by “careless companies putting many Americans’ hard-earned cash to great risk,” Brown said.

Stablecoins on the Spot

The “crypto crash” hearing came after a regulatory clampdown on the BUSD stablecoin by the blockchain company Paxos. The regulator ordered Paxos to cease distributing its stablecoin, citing a number of unresolved issues. Paxos in turn told its clients to redeem their stablecoins either in U.S. dollars or any other stablecoin issued by the same company. The Securities and Exchange Commission intends to sue Paxos on the grounds that BUSD was to be registered under the federal securities laws, but this didn’t happen.

Enforcement Is Beefed Up

The latest regulatory crackdown on BUSD and Paxos has had the crypto enthusiasts in confusion, says Marcus Sotirou, a digital asset market analyst. Many view this muscle flexing by the regulators as unfair since it is targeting the nascent industry. The regulators have cautioned U.S. banks against the fraud risks and volatility of the crypto biosphere.

Needless to say, blockchain industry actors such as Bit Digital Inc. (NASDAQ: BTBT) long for an environment that has clear regulations which can guide their operations, rather than the current reality of enforcement action without industry guidelines.

Bit Digital Inc. (BTBT), closed Tuesday's trading session at $1.41, off by 5.3691%, on 1,470,753 volume. The average volume for the last 3 months is 23.462M and the stock's 52-week low/high is $0.5301/$4.26.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, QualityStocks, MarketClub Analysis, The Street, Early Bird, StockEarnings, MarketBeat, StocksEarning, Kiplinger Today, The Online Investor, Daily Trade Alert, Investopedia, Trades Of The Day, INO Market Report, Louis Navellier, The Wealth Report, The Stock Dork, AllPennyStocks, Wealth Whisperer, Zacks and InvestorsUnderground reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The dramatic price reductions made by Tesla last month contributed to a $3,300 decrease in the average cost of a newly purchased electric car throughout the United States. Based on a report from Kelley Blue Book (KBB), a company for vehicle valuation, the average cost of an electric car in December was $62,088 but dropped to $58,725 in January.

Tesla vehicles cost an average of $59,648 in January, lower than $65,080 in December. The price reductions made by Tesla on Jan. 13, 2023, are the cause of the reduced selling prices. These price drops are aimed at boosting sales and expanding the number of vehicles that qualify for the $7,500 new EV tax credits.

Following this, Tesla has changed its vehicle prices multiple times. For instance, Tesla’s Model 3 car, which was previously priced at $46,990 before the price adjustments, is now priced at $42,990, and the Model Y SUV’s starting price is at $54,990, which is lower than $65,990 previously.

A year ago, these two Tesla Models 3 and Y were by far the most preferred electric vehicles. A separate report indicated that the cost of secondhand Tesla vehicles has also decreased dramatically recently. Tesla accounts for nearly two-thirds of the overall electric vehicle market, so the price reductions had a substantial effect on the average price of electric vehicles, as reported by Kelley Blue Book.

The price cuts have made Tesla vehicles significantly more cost effective, and customers are making the most of the opportunity to purchase vehicles. According to the KBB report, sales increased by 30 percent in the month following the price reduction compared to January of this year, implying that the lower prices likely assisted Tesla in delivering higher sales volumes.

Following Tesla’s lead, Ford announced price reductions between $600 and $5,900 for its electric Mustang Mach-E SUVs for the period ending January 2023. In addition, Lucid, a premium manufacturer of electric vehicles, revealed that it was giving tax credits of up to $7,500 on a few of its models that are not eligible for the tax credit being offered by the government because they are too costly.

It’s not just electric cars that are becoming more affordable —most cars are seeing price reductions. During January 2023, the average cost of a newly purchased car fell by $310 to $49,388 after hitting a record high last year in December. But, compared to other types of vehicles, the average cost of electric vehicles fell last month by a much greater margin.

As models from automakers such as Lucid Motors (NASDAQ: LCID) become more affordable, more consumers could make the switch and accelerate the transition to electrified transport.

Lucid Motors (LCID), closed Tuesday's trading session at $9.9, off by 9.4236%, on 23,461,549 volume. The average volume for the last 3 months is 889,565 and the stock's 52-week low/high is $6.09/$29.0499.

Southern Copper Corporation (SCCO)

MarketBeat, SmarTrend Newsletters, InvestorPlace, The Street, Louis Navellier, The Online Investor, QualityStocks, Daily Wealth, Daily Trade Alert, TopStockAnalysts, The Wealth Report, Trades Of The Day, StreetAuthority Daily, Zacks,, Barchart, Money Morning, TheStockAdvisor, Early Bird, Kiplinger Today, Market Intelligence Center Alert, Schaeffer's, MarketClub Analysis, Top Pros' Top Picks, Market Authority, The Growth Stock Wire, Uncommon Wisdom, Investopedia, StreetInsider, TheStockAdvisors, ChartAdvisor, Market Report, The Stock Enthusiast, Investiv, InvestmentHouse, Investment House, Investing Futures, Greenbackers, Forbes, DrStockPick, Dividend Opportunities, CRWEWallStreet, CRWEPicks, CRWEFinance, Cabot Wealth, BestOtc, AllPennyStocks, DividendStocks, StockHotTips, Wealth Insider Alert, Wealth Daily, Vantage Wire, TradingMarkets, TradingAuthority Daily, The Tycoon Report, The Trading Report, The Motley Fool, Streetwise Reports, MarketDNA, StockLockandLoad, Investor Update, Profit Confidential, PennyToBuck, PennyOmega, Navellier Growth, Money and Markets, 24/7 Trader, InvestorsObserver Team, InvestorIntel, InvestorGuide and StockRockandRoll reported earlier on Southern Copper Corporation (SCCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Analysts expect that the global market will experience a copper shortage this year that may last until 2030. The red metal will play a crucial role in the energy transition, given its use in industrial machinery and electrical equipment. Higher demand pressures and challenges affecting the South American supply chains are fueling the metal’s shortage.

A copper squeeze may signal that inflationary pressures will worsen globally, which may, in turn, push central banks to lengthen their hawkish stance.

Robin Griffin, VP of Metals and Mining at Wood Mackenzie, stated that the firm had forecasted major copper deficits to 2030. Griffin mainly attributed the deficit to higher demand for the metal in the energy transition and the ongoing unrest in Peru, which had led to mine closures.

Since former President Pedro Castillo was ousted late last year following an impeachment trial, Peru has been experiencing internal conflicts. Castillo was arrested after attempting to dissolve Congress in a bid to cling to power.

Peru makes up 10% of copper supply globally, coming second to Chile.

Last month, Glencore announced that it would be halting operations in its Antapaccay copper mine, following a looting and fire at its premises.

Chile, which is the biggest supplier of copper globally, also recorded a 7% decline in production in November 2022. In a note, Goldman Sachs stated that it expected Chile to reduce copper production between 2023 and 2030.

China’s reopening has put a further strain on the red metal, with one CMC Markets analyst noting that this move will greatly impact copper’s price, especially with the current shortage, making mining harder. Tina Teng, the analyst in question, argued that China’s economic recovery and increase in demand would also cause the price of copper to double in the near-term.

Not all share this sentiment, however, with Wolfe Research’s MD Timna Tanners noting that she did not expect a huge surge in consumption of copper as China recovered. Tanners also posited that the number of copper mines in operation may increase this year, adding that broader electrification would greatly drive copper demand. She explained that building charging infrastructure for electric vehicles would be even more copper intensive.

Data from the IEA shows that in 2021, the sale of electric vehicles increased significantly, bringing the total number of electric cars globally to roughly 16.5 million. This means that the electric car-charging ecosystem will need to be boosted to meet expected future demand.

As copper inventories around the world become squeezed, copper extractors such as Southern Copper Corporation (NYSE: SCCO) are likely to increasingly become the subject of investor interest.

Southern Copper Corporation (SCCO), closed Tuesday's trading session at $74.36, up 0.432199%, on 917,745 volume. The average volume for the last 3 months is 435,934 and the stock's 52-week low/high is $42.42/$79.315.

Compass Pathways PLC (CMPS)

QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scores of studies on the therapeutic potential of psychedelic substances have been conducted these last 20 years, with promising results showing that drugs such as MDMA, LSD and psilocybin may be useful in the treatment of various mental health conditions. These positive findings have fueled the psychedelics decriminalization and legalization movement greatly, despite the fact that the substances are illegal at the federal level.

While numerous studies have been done on classic psychedelics, not enough studies have featured mescaline. Mescaline is a naturally occurring psychedelic that induces hallucinogenic effects when consumed. Some pharmacological companies and researchers have been trying to find associations between mescaline and other classic psychedelics, with a focus on the drug’s broader therapeutic use.

Anecdotal studies highlight that mescaline could be useful in the treatment of various mental health conditions. For instance, one survey conducted in 2021 looked into the use of mescaline in managing symptoms of mental illness. The survey’s findings show that the use of mescaline improved the symptoms of 86% of participants with depression. Participants also reported improvements in their symptoms of PTSD, anxiety, alcohol-use disorder and substance-use disorder.

So, why is research on the drug trailing behind other psychedelics if the substance may be beneficial to mental health patients?

The main reason why research into this compound has failed to keep pace with other psychedelics is its availability, which is wanting. University of Alabama clinical psychologist Peter Hendricks also believes that the side effects and potency of mescaline may also be contributory to the lack of enough research on the drug. Hendricks explains that nausea was a common side effect of mescaline consumption, noting that this was caused by the drug’s rapid absorption into the gastrointestinal tract.

The drug’s psychoactive effect also last roughly 12 hours, which reduces the chances of its administration as a therapy being covered by insurance. Additionally, the use of mescaline-containing entheogens such as peyote in spiritual and cultural practices by the Native American Church and other indigenous peoples makes it difficult to do conduct trials using the drug.

This is mainly because the widespread use of the drug would boost demand for the already threatened cactus, making it harder for those with religious exemptions to access the drug.

It doesn’t help that development has led to a rapid decline in the areas where peyote can be harvested in America. To counter this, researchers and research companies are advised to use other mescaline-containing cacti that aren’t considered threatened, such as the San Pedro cacti.

Synthesizing mescaline in a laboratory is also preferred, because it eliminates chances of overharvesting.

As enterprises such as Compass Pathways PLC (NASDAQ: CMPS) advance their R&D programs focusing on psychedelics, the world is likely to see medicinal formulations addressing previously underserved or unmet clinical needs in the mental health field.

Compass Pathways PLC (CMPS), closed Tuesday's trading session at $8.68, off by 4.9288%, on 435,934 volume. The average volume for the last 3 months is 49 and the stock's 52-week low/high is $6.54/$21.50.

The QualityStocks Company Corner

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

Agricultural digestion produces biogas by breaking down organicmatter, including livestock manure, crop residues, and food waste

Biogas is purified to create renewable natural gas, fullycompatible with existing pipeline networks

EverGen currently owns and operates five RNG and/or organicprocessing facilities across Canada

RNG produced at Fraser Valley Biogas, Net Zero Waste Abbottsford,and GrowTEC bought by large Canadian utility company via long-termofftake agreement

Agricultural digestion produces biogas by breaking down organicmatter such as livestock manure, crop residues, and food waste. Thebiogas is then purified of water vapor, sulfide, siloxanes, andhydrogen sulfide to create renewable natural gas - anenvironmentally friendly alternative that is fully compatible withexisting pipeline networks.EverGen (TSX.V: EVGN) (OTCQB: EVGIF) announced that its Sea to Sky Soils organic waste processing andcomposting facility has entered multiple contracts with a B.C.regional district for the processing of organic waste at thefacility, which provides over 10,000 tonnes per annum. With a trackrecord of operational excellence and sustainable practices, EverGenis one of the top regional processors of organics in B.C. Thecompany’s commitment is to own and operate best-in-class facilitiesthat offer its municipal and commercial partners bothcost-effective and environmentally sustainable solutions forprocessing and recycling organics. “Contracts such as these de-riskour core business and represent another step towards our goal ofproviding solutions for over 300,000 tonnes of organic waste perannum in the region,” said Chase Edgelow, CEO of EverGen. To viewthe full press release, visit

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Tuesday's trading session at $2.37, even for the day. The average volume for the last 3 months is 501 and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

In only a few short years, the cannabis industry has proven to beone of the fastest-growing and most profitable sectors in the country. Over two decades afterCalifornia legalized medical cannabis, the marijuana industry has grown to a behemoth sector worthbillions of dollars. The industry has sold billions’ worth ofcannabis products, filled state coffers with billions of dollars in taxes and created hundreds of thousands of new employment opportunities.This landscape of constant growth and runaway profits attractedentrepreneurs from all over the country who were itching to gain aportion of the extremely lucrative cannabis market for themselves.However, this quickly resulted in an oversaturation of supply as more sellers jumped into the mix, crowding the market. It canbe quite difficult to stand out in such an oversaturated market,especially if your business is located in a region such asMichigan, which has no statewide cap on the number of marijuana business licenses. Furthermore, it provides clearmarketing performance indicators and makes it possible formarketers to track the effectiveness of their tactics over the longterm. These metrics are also helpful to firms like Advanced Container Technologies Inc. (OTC: ACTX) which are ancillary to the cannabis space.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.44, up 15.6373%, on 501 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.00/$.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • Coyuchi, the gold standard in sustainable luxury home goods,has not only pushed the sustainability conversation forward butalso lived it in all of its operations
  • Its unique market positioning has seen its net income grow by26% YOY between 2020 and 2021, with a return customer rate of35% over 24 months
  • The company’s management is optimistic that 2023 will be agreat year, with the foundations laid so far playing a pivotalrole in its growth. One of the critical areas to be exploredwill be partnerships with retailers
  • Coyuchi’s commitment to sustainability and circular design willalso continue to play a role in the company’s growth in 2023.Its management is confident that its current positioning willtake advantage of the growth within the global organic cottonmarket, allowing Coyuchi to stamp its position and continueplaying a key role in its space

Coyuchi, the gold standard in sustainable luxury home goods, is entering anew phase of growth in the wake of the increasing consideration ofand investment in sustainability at scale. As a company that hasbuilt its brand around offering sustainably-produced luxury organicbedding, sheets, towels, apparel, and other home goods for theenvironmentally conscious home, Coyuchi has not only pushed thesustainability conversation forward but also lived it through itsoperations.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • REZYFi is a real estate-oriented mortgage company servicing theneeds of licensed and permitted cannabis companies and ownersof real estate who lease to cannabis companies
  • The average rate on a 30-year-fixed-rate mortgage, measuredweekly, has been declining gradually since October last year,increasing the market for new and refinanced mortgages
  • Mortgage refinancing can be a source of capital, presenting animportant financing opportunity for business operators in thecannabis space who struggle to access money from traditionalbanks

In the months since the US average rate on a 30-year-fixed-ratemortgage peaked at more than 7.10% in October last year, the valuehas been gradually declining. According to Freddie Mac’s weeklymortgage rate survey, the average rate stood at 6.12% as ofFebruary 9, 2023, a slight increase from the 6.09% average recordeda week earlier on February 2, 2023 ( This general softening has had a ripple effect. Operators withinthe cannabis industry have long struggled with access to capital inthe form of mortgages and loans. This is because most traditionalbanks and financial institutions, which are insured by the FederalDeposit Insurance Corporation (“FDIC”), are prohibited fromoffering financial services or loans to cannabis companies. So, thedeclining average mortgage rates are a boon for business owners inthis space, and companies like REZYFi are on standby to help such proprietors.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

President Biden proclaims February as American Heart Month

Annual tradition provides opportunity to focus on nationwideproblem of heart and blood-vessel diseases

HeartBeam is committed to being part of the solution foridentifying, treating heart attacks

Following a decades-long tradition, President Joseph Biden issued aproclamation from the White House declaring February as AmericanHeart Month ( This nationwide focus on heart health is fully supported by HeartBeam (NASDAQ: BEAT), a cardiac technology company dedicated to leading the way infinding effective ways to detect heart attacks earlier than everbefore.HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, is featured in a recentinterview with David Leichner that was published in “Authority”magazine. The interview was one of a series of interviews withleaders of tech companies. The series, called “Technology Making anImportant Positive Social Impact,” spotlights companies working onmaking monumental positive changes to society, health, and theenvironment. In the interview, Vajdic talked about his journey toHeartBeam, including the first half of his career, which was spentas a chip designer with Intel Corporation; Vajdic was involved inthe design of the first Flash memory, including two patents thattransformed Flash from an idea to a product. During the lastdecade-plus, Vajdic has focused on developing cardiovasculardevices with a vision to enable rapid, accurate heart attackdetection outside of a medical setting. During the interview,Vajdic described himself as a risk taker and observed that “thereis no progress without some significant risk.” He explained thatHeartBeam is developing technology that “offers the ability todetermine if chest pain or other cardiac symptoms are due to aheart attack, any time, any place. Timely intervention will savemany lives,” said HeartBeam CEO and founder Branislav Vajdic, PhD,during the interview. “Our product in development, HeartBeamAIMIGo(TM), is a portable, credit-card-sized device designed to beplaced on the chest to take ECG recordings that are immediatelytransmitted to a clinician for review. This enables a clinician todetermine if that patient needs to go to an ER and/or call 911, orif they can stay home and continue with their day. To make thatdetermination, the clinician needs to have a standard-of-care,12-lead electrocardiogram (“ECG”), a symptom report and patienthistory. The HeartBeam platform provides all of that information.”To view the full interview, visit

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.


HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $3.57, off by 4.2895%, on 44,304 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria’s patented DehydraTECH(TM) technology improves how APIsenter the bloodstream through the promotion of healthier oralingestion methods while also increasing the effectiveness offat-soluble active molecules

As a disruptive technology, its impact has been felt by otherplayers in its space, leading Lexaria to open its doors topartnering with industry experts and implementing the technologyacross many fields, including licensing the technology to Fortune100 companies

Lexaria will continue to make its technology accessible, improvingthe lives of people around the world

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016,repeatedly demonstrated the potential of its patented technology,DehydraTECH(TM). The technology improves how active pharmaceuticalingredients (“APIs”) enter the bloodstream by promoting healthieroral ingestion methods while increasing the effectiveness offat-soluble active molecules. With the help of this technology,Lexaria has explored potential treatment options for a variety ofconditions, including hypertension, epilepsy, and even nicotinereplacement.Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reportingadditional findings from its human clinical study HYPER-H21-4; thestudy is designed to demonstrate a potentially novel mechanism ofaction of LEXX’s patented DehydraTECH-processed cannabidiol ("CBD")capsule formulation in the treatment of blood pressure ("BP").According to the announcement, Lexaria believes that thosefindings, which were published in the peer-reviewed “Biomedicineand Pharmacotherapy" journal, could support DehydraTECH-CBDqualification within existing Food and Drug Administration (“FDA”)guidelines. Previous results of the study indicated that primaryefficacy and safety objectives were successfully achieved,including hypertensive patients seeing resting blood pressuresignificantly reduced and sustained over the full five weeks ofdosing; results also showed that no serious adverse events havebeen reported during the study. To view the full press release,visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.97, off by 2.293%, on 52,501 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion (NASDAQ: FNGR), a mobile data and services company, today announced the outcomeof matters voted on at its recent annual meeting of stockholders,which took place on Feb. 17, 2023. Among the highlights, HsienLoong Wong, Yew Poh Leong, Michael Chan and Eng Ho Ng were electedto the company’s board of directors, Centurion ZD CPA & Co. wasappointed as FNGR’s independent registered public accounting firm,and the company’s 2023 Stock Incentive Plan, executive compensationand the amendment to the exercise price of outstanding stockoptions from $8.00 to $3.84 were approved. In addition,FingerMotion’s executive officers were re-appointed by its board ofdirectors immediately following the annual meeting as detailed inthe announcement.

To view the full press release, visit

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $2.46, off by 13.986%, on 140,292 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.62/$9.795.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development andmanufacturing of rare cannabinoids and cannabinoid analogs, isreporting on its second quarter of fiscal year 2023, the periodthat ended Dec. 31, 2022. Highlights of the report include thecompany closing the calendar year with nearly $11.5 million in cashand the completion of enrollment in the company’s phase 2 clinicaltrial in epidermolysis bullosa (“EB”). The report also noted thatthe company has seen advancement in its research using rarecannabinoids in the treatment of glaucoma and neurodegenerativediseases such as Alzheimer’s, Huntington’s and Parkinson’s. “Thisperiod was another strong operational quarter for the company as weadvanced our pharmaceutical programs, including the launch ofINM-900 series compounds for the evaluation of neurodegenerativediseases,” said InMed Pharmaceuticals president and CEO Eric A.Adams in the press release. “We are currently approaching the endof enrollment in our phase 2 clinical trial in epidermolysisbullosa. As we move into calendar 2023, we have a strong pipelineof programs at various stages of development. Fiscal Q2 sawsignificant cost savings across the different business segmentsresulting in a reduced cash burn. In addition, our strong cashposition of over $11 million enables us to pursue several materialmilestones throughout calendar 2023.”

To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $1.48, off by 7.5%, on 136,993 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.23/$35.50.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue lightemergency communication systems, sees continued growth throughsales of 11 K1 Call Boxes to Larimer County, Colorado. Thetransaction was completed through KSCP resale partner Stream SpeedTechnologies (“SST”). Knightscope’s smallest emergency call boxsystem, the K1 Call Box, offers one-touch connection with aruggedized housing and simple interface. The call box offers acompletely wireless solution for emergency phone calls and can alsowork with existing nearby wiring nearby. In addition, the systemincludes additional options that allow people who are deaf, hard ofhearing or speech-impaired to communicate via the telephone. Thesenew sales are part of Knightscope’s consistent momentum headinginto the new year, which has included more than 30 new sales and 7client renewals. In addition, Knightscope Autonomous SecurityRobots have collectively amassed more than 2 million hours of paidfield operations. To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $1.1, off by 4.3478%, on 402,115 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.10/$8.42.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

A recently conducted survey has highlighted a clear disparity regarding the perceptions and experiences of pain in women and men. The survey, which involved more than5,000 individuals aged between 18 and 65 year old, found that about50% of women did not receive needed support from their generalpractitioners when they tried getting help for their pain. Thisproportion is quite high, especially when compared to the 36% ofmen who experienced the same. Roughly 63% of women also revealedthat they felt men’s pain was deemed more serious because of genderdiscrimination by healthcare professionals. Additionally, more than55% of women admitted to being ignored or dismissed as emotionalwhen they brought up their pain. As the years go by and companiessuch as India Globalization Capital Inc. (NYSE American: IGC) commercialize new pain treatments from cannabis, all patientsregardless of their gender will have a chance of getting a moreeffective remedy to their pain.

Despite polls showing that most Americans favor legalizing cannabisand the fact that it has spread to red states such as Missouri where adult-use sales began last week, some lawmakers andlobbyists still think that major, revolutionary change such as federal legalization is still a long way off.Even though there are some encouraging signs in Congress, such assupport from South Carolina Representative Nancy Mace, there isstill plenty of opposition, and the House appears to have “a lot onits plate” right now. Mace is a prominent conservative advocate formarijuana legalization. One significant barrier is the perceptionthat marijuana is not a priority for House Speaker Kevin McCarthy,who represents a conservative region of California where retaildispensaries for legal commercial cannabis are prohibited. There isalso an understanding that crucial committees wheremarijuana-related legislation needs to be heard will instead act asroadblocks. One example is the House Judiciary Committee, which iscurrently led by Jim Jordan, an Ohio Republican. The way thingsstand, enterprises looking to medicalize marijuana compounds suchas India Globalization Capital Inc. (NYSE American: IGC) have a more certain outlook compared to those that are banking onfederal policy reform.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.382, off by 0.984966%, on 121,551 volume. The average volume for the last 3 months is 113,243 and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel (OTCQB: SDCH), a provider of cybersecurity products and services to emerging,middle-market and enterprise companies, today announced the resultsof its annual meeting of stockholders and summarized highlightsfrom its Investor Day broadcast, both of which occurred on Feb. 15, 2023. Results of the annualmeeting included new board appointments, the ratified appointmentof RBSM, LLP as the company’s independent auditor, and the grantingof discretionary authority to the board of directors to combineoutstanding shares of SideChannel’s common stock into a lessernumber of outstanding shares, with the exact ratio to be determinedby the board. During the live-streamed investor day, CEO BrianHaugli and CFO Ryan Polk discussed SDCH’s value proposition,including factors underpinning the growing demand for SideChannel’scybersecurity program leadership and the company’s recentlyannounced quarterly revenue growth. “We appreciate the stockholderapproval of our annual meeting proposals. We are committed toincreasing direct engagement with our stockholders and were pleasedwith the participation at our investor day,” said Brian Haugli.“Our team is delivering meaningful leadership to our clients, andwe want our stockholders to understand why mid-market companiesappreciate what we do and why cybersecurity professionals lovebeing on the SideChannel team.”

To view the full press release, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Tuesday's trading session at $0.115, off by 4.1667%, on 12,983 volume. The average volume for the last 3 months is 12,983 and the stock's 52-week low/high is $0.0675/$0.18.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Adoption of zero-emission vehicles accelerated across almost allmarkets and vehicle segments in 2022 and will continue on the backof increasing government regulation and incentives

Power inverters, irreplaceable power conversion tech, has receiveda meaningful upgrade with Hillcrest’s ZVS inverter technology thatimproves operating power and efficiency

Hillcrest anticipates commitments for commercial revenue this yearfrom its inverter as it expands into multiple other areas where thetechnology is highly applicable

New technologies are always accompanied by unforeseen challenges,especially for the EV space as it is becoming more and morepronounced. There was a time when people thought the idea of ahorseless carriage moving around was impossible. Ironically,electric vehicles came about before those powered by gasoline. Atthe time, gasoline was cleaner and more reliable, so electricsdisappeared from the market. With the outset of the new electricvehicle revolution, questions have abounded about a slew of topics,such as safety, range anxiety, and charging infrastructure. Expertsare still trying to square circles regarding who will pay forelectric grid upgrades, while others like Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) emerge on the scene with innovations tackling heat and powerissues that sap efficiency from EVs.

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Tuesday's trading session at $0.0644, off by 1.3027%, on 2,800 volume. The average volume for the last 3 months is 2,800 and the stock's 52-week low/high is $0.0584/$0.1468.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.